ID   OMM2.5
AC   CVCL_C307
SY   Omm2.5; OMM2_5; OMM25; OMM1.5; Omm1_5
DR   cancercelllines; CVCL_C307
DR   Cell_Model_Passport; SIDM01843
DR   Cosmic; 916146
DR   Cosmic; 1628398
DR   DepMap; ACH-002018
DR   Wikidata; Q54936373
RX   PubMed=9247253;
RX   PubMed=22236444;
RX   PubMed=23849826;
RX   PubMed=24994677;
RX   PubMed=28018010;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Ksander B.; Schepens Eye Research Institute; Boston; USA.
CC   Doubling time: 50 hours (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=22236444).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): DepMap=ACH-002018; PubMed=22236444; PubMed=24994677
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 19
ST   D21S11: 28,29
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 8,13
ST   FGA: 26 (PubMed=22236444)
ST   FGA: 26,27 (DepMap=ACH-002018)
ST   Penta D: 15,16
ST   Penta E: 8,10
ST   TH01: 6,9
ST   TPOX: 10
ST   vWA: 17,18
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C302 ! Mel270
OI   CVCL_C305 ! OMM2.2
OI   CVCL_C306 ! OMM2.3
OI   CVCL_C308 ! OMM2.6
SX   Male
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 19
//
RX   PubMed=9247253; DOI=10.1023/A:1018479011340;
RA   Chen P.W., Murray T.G., Uno T., Salgaller M.L., Reddy R.,
RA   Ksander B.R.;
RT   "Expression of MAGE genes in ocular melanoma during progression from
RT   primary to metastatic disease.";
RL   Clin. Exp. Metastasis 15:509-518(1997).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by gefitinib and cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//
RX   PubMed=28018010;
RA   Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.;
RT   "Uveal melanoma cell lines: where do they come from? (an American
RT   Ophthalmological Society thesis).";
RL   Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016).
//